PASG

SEC source: 0000947871-25-000021 · ownership.xml · nonDerivative · entry 1

ORBIMED ADVISORS LLC · CIK 0001055951 · 10% owner

OrbiMed Capital GP VII LLC · CIK 0001760648 · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: No plan indicated

Ownership: Indirect · See footnotes

Disclosed balance after: 7,385,388

F1 · price: Represents the weighted average sale price of the shares of the Issuer's common stock sold, ranging from a low of $0.76 to a high of $0.79 per share. The Reporting Persons undertake, upon request by the staff of the Securities and Exchange Commission, the Issuer, or a securityholder of the Issuer, to provide full information regarding the number of shares sold at each separate price.

F4 · ownership.nature: These shares of the Issuer's common stock are held of record by OrbiMed Private Investments VII, LP ("OPI VII"). OrbiMed Capital GP VII LLC ("GP VII") is the general partner of OPI VII, and OrbiMed Advisors LLC ("OrbiMed Advisors"), a registered investment adviser under the Investment Advisors Act of 1940, as amended, is the managing member of GP VII. By virtue of such relationships, GP VII and OrbiMed Advisors may be deemed to have voting and investment power over the shares of common stock held by OPI VII and, as a result, may be deemed to have beneficial ownership over such shares of common stock. OrbiMed Advisors exercises this investment and voting power through a management committee comprised of Carl L. Gordon, Sven H. Borho, and W. Carter Neild, each of whom disclaims beneficial ownership over the shares of common stock held by OPI VII.

F5 · ownership.nature: Each of OrbiMed Advisors and GP VII disclaims beneficial ownership of the securities reported herein for purposes of Rule 16a-1(a) under the Securities Exchange Act of 1934, as amended (the "Exchange Act"), except to the extent of its pecuniary interest therein, if any. This report shall not be deemed an admission that any such entity is a beneficial owner of such securities for the purpose of Section 16 of the Exchange Act, or for any other purpose.

SEC source: 0000902664-24-007075 · ownership.xml · nonDerivative · entry 1

Lynx1 Capital Management LP · CIK 0001910456 · 10% owner

Nichols Weston · CIK 0001746376 · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: No plan indicated

Ownership: Indirect · See footnote

Disclosed balance after: 9,256,953

F1 · price: The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $0.6426 to $0.65 inclusive. The Reporting Persons undertake to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth herein.

F2 · ownership.nature: The securities to which this filing relates are held directly by Lynx1 Master Fund LP to which Lynx1 Capital Management LP (the "Investment Manager") serves as investment manager. Weston Nichols ("Mr. Nichols") is the sole member of Lynx1 Capital Management GP LLC, the general partner of the Investment Manager. Each of the Investment Manager and Mr. Nichols disclaims beneficial ownership of the securities to which this filing relates for purposes of Section 16 of the Securities and Exchange Act of 1934, as amended, except to the extent of his or its pecuniary interest therein, if any.

SEC source: 0000947871-24-001037 · ownership.xml · nonDerivative · entry 1

ORBIMED ADVISORS LLC · CIK 0001055951 · 10% owner

OrbiMed Capital GP VII LLC · CIK 0001760648 · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: No plan indicated

Ownership: Indirect · See footnotes

Disclosed balance after: 7,404,869

F1 · ownership.nature: These shares of the Issuer's common stock are held of record by OrbiMed Private Investments VII, LP ("OPI VII"). OrbiMed Capital GP VII LLC ("GP VII") is the general partner of OPI VII, and OrbiMed Advisors LLC ("OrbiMed Advisors"), a registered investment adviser under the Investment Advisors Act of 1940, as amended, is the managing member of GP VII. By virtue of such relationships, GP VII and OrbiMed Advisors may be deemed to have voting and investment power over the shares of common stock held by OPI VII and, as a result, may be deemed to have beneficial ownership over such shares of common stock. OrbiMed Advisors exercises this investment and voting power through a management committee comprised of Carl L. Gordon, Sven H. Borho, and W. Carter Neild, each of whom disclaims beneficial ownership over the shares of common stock held by OPI VII.

F2 · ownership.nature: Each of OrbiMed Advisors and GP VII disclaims beneficial ownership of the securities reported herein for purposes of Rule 16a-1(a) under the Securities Exchange Act of 1934, as amended (the "Exchange Act"), except to the extent of its pecuniary interest therein, if any. This report shall not be deemed an admission that any such entity is a beneficial owner of such securities for the purpose of Section 16 of the Exchange Act, or for any other purpose.

SEC source: 0000947871-24-000998 · ownership.xml · nonDerivative · entry 3

ORBIMED ADVISORS LLC · CIK 0001055951 · 10% owner

OrbiMed Capital GP VII LLC · CIK 0001760648 · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: No plan indicated

Ownership: Indirect · See footnotes

Disclosed balance after: 7,635,190

F3 · ownership.nature: These shares of the Issuer's common stock are held of record by OrbiMed Private Investments VII, LP ("OPI VII"). OrbiMed Capital GP VII LLC ("GP VII") is the general partner of OPI VII, and OrbiMed Advisors LLC ("OrbiMed Advisors"), a registered investment adviser under the Investment Advisors Act of 1940, as amended, is the managing member of GP VII. By virtue of such relationships, GP VII and OrbiMed Advisors may be deemed to have voting and investment power over the shares of common stock held by OPI VII and, as a result, may be deemed to have beneficial ownership over such shares of common stock. OrbiMed Advisors exercises this investment and voting power through a management committee comprised of Carl L. Gordon, Sven H. Borho, and W. Carter Neild, each of whom disclaims beneficial ownership over the shares of common stock held by OPI VII.

F4 · ownership.nature: Each of OrbiMed Advisors and GP VII disclaims beneficial ownership of the securities reported herein for purposes of Rule 16a-1(a) under the Securities Exchange Act of 1934, as amended (the "Exchange Act"), except to the extent of its pecuniary interest therein, if any. This report shall not be deemed an admission that any such entity is a beneficial owner of such securities for the purpose of Section 16 of the Exchange Act, or for any other purpose.

SEC source: 0000947871-24-000998 · ownership.xml · nonDerivative · entry 2

ORBIMED ADVISORS LLC · CIK 0001055951 · 10% owner

OrbiMed Capital GP VII LLC · CIK 0001760648 · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: No plan indicated

Ownership: Indirect · See footnotes

Disclosed balance after: 7,635,270

F2 · price: Represents the weighted average sale price of the shares of the Issuer's common stock sold, ranging from a low of $0.80 to a high of $0.8094 per share. The Reporting Persons undertake, upon request by the staff of the Securities and Exchange Commission, the Issuer, or a securityholder of the Issuer, to provide full information regarding the number of shares sold at each separate price.

F3 · ownership.nature: These shares of the Issuer's common stock are held of record by OrbiMed Private Investments VII, LP ("OPI VII"). OrbiMed Capital GP VII LLC ("GP VII") is the general partner of OPI VII, and OrbiMed Advisors LLC ("OrbiMed Advisors"), a registered investment adviser under the Investment Advisors Act of 1940, as amended, is the managing member of GP VII. By virtue of such relationships, GP VII and OrbiMed Advisors may be deemed to have voting and investment power over the shares of common stock held by OPI VII and, as a result, may be deemed to have beneficial ownership over such shares of common stock. OrbiMed Advisors exercises this investment and voting power through a management committee comprised of Carl L. Gordon, Sven H. Borho, and W. Carter Neild, each of whom disclaims beneficial ownership over the shares of common stock held by OPI VII.

F4 · ownership.nature: Each of OrbiMed Advisors and GP VII disclaims beneficial ownership of the securities reported herein for purposes of Rule 16a-1(a) under the Securities Exchange Act of 1934, as amended (the "Exchange Act"), except to the extent of its pecuniary interest therein, if any. This report shall not be deemed an admission that any such entity is a beneficial owner of such securities for the purpose of Section 16 of the Exchange Act, or for any other purpose.

SEC source: 0000947871-24-000998 · ownership.xml · nonDerivative · entry 1

ORBIMED ADVISORS LLC · CIK 0001055951 · 10% owner

OrbiMed Capital GP VII LLC · CIK 0001760648 · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: No plan indicated

Ownership: Indirect · See footnotes

Disclosed balance after: 7,643,285

F1 · price: Represents the weighted average sale price of the shares of the Issuer's common stock sold, ranging from a low of $0.80 to a high of $0.87 per share. The Reporting Persons undertake, upon request by the staff of the Securities and Exchange Commission, the Issuer, or a securityholder of the Issuer, to provide full information regarding the number of shares sold at each separate price.

F3 · ownership.nature: These shares of the Issuer's common stock are held of record by OrbiMed Private Investments VII, LP ("OPI VII"). OrbiMed Capital GP VII LLC ("GP VII") is the general partner of OPI VII, and OrbiMed Advisors LLC ("OrbiMed Advisors"), a registered investment adviser under the Investment Advisors Act of 1940, as amended, is the managing member of GP VII. By virtue of such relationships, GP VII and OrbiMed Advisors may be deemed to have voting and investment power over the shares of common stock held by OPI VII and, as a result, may be deemed to have beneficial ownership over such shares of common stock. OrbiMed Advisors exercises this investment and voting power through a management committee comprised of Carl L. Gordon, Sven H. Borho, and W. Carter Neild, each of whom disclaims beneficial ownership over the shares of common stock held by OPI VII.

F4 · ownership.nature: Each of OrbiMed Advisors and GP VII disclaims beneficial ownership of the securities reported herein for purposes of Rule 16a-1(a) under the Securities Exchange Act of 1934, as amended (the "Exchange Act"), except to the extent of its pecuniary interest therein, if any. This report shall not be deemed an admission that any such entity is a beneficial owner of such securities for the purpose of Section 16 of the Exchange Act, or for any other purpose.

SEC source: 0000947871-24-000995 · ownership.xml · nonDerivative · entry 2

ORBIMED ADVISORS LLC · CIK 0001055951 · 10% owner

OrbiMed Capital GP VII LLC · CIK 0001760648 · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: No plan indicated

Ownership: Indirect · See footnotes

Disclosed balance after: 7,697,466

F2 · price: Represents the weighted average sale price of the shares of the Issuer's common stock sold, ranging from a low of $0.81 to a high of $0.83 per share. The Reporting Persons undertake, upon request by the staff of the Securities and Exchange Commission, the Issuer, or a securityholder of the Issuer, to provide full information regarding the number of shares sold at each separate price.

F3 · ownership.nature: These shares of the Issuer's common stock are held of record by OrbiMed Private Investments VII, LP ("OPI VII"). OrbiMed Capital GP VII LLC ("GP VII") is the general partner of OPI VII, and OrbiMed Advisors LLC ("OrbiMed Advisors"), a registered investment adviser under the Investment Advisors Act of 1940, as amended, is the managing member of GP VII. By virtue of such relationships, GP VII and OrbiMed Advisors may be deemed to have voting and investment power over the shares of common stock held by OPI VII and, as a result, may be deemed to have beneficial ownership over such shares of common stock. OrbiMed Advisors exercises this investment and voting power through a management committee comprised of Carl L. Gordon, Sven H. Borho, and W. Carter Neild, each of whom disclaims beneficial ownership over the shares of common stock held by OPI VII.

F4 · ownership.nature: Each of OrbiMed Advisors and GP VII disclaims beneficial ownership of the securities reported herein for purposes of Rule 16a-1(a) under the Securities Exchange Act of 1934, as amended (the "Exchange Act"), except to the extent of its pecuniary interest therein, if any. This report shall not be deemed an admission that any such entity is a beneficial owner of such securities for the purpose of Section 16 of the Exchange Act, or for any other purpose.

SEC source: 0000947871-24-000995 · ownership.xml · nonDerivative · entry 1

ORBIMED ADVISORS LLC · CIK 0001055951 · 10% owner

OrbiMed Capital GP VII LLC · CIK 0001760648 · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: No plan indicated

Ownership: Indirect · See footnotes

Disclosed balance after: 7,718,369

F1 · price: Represents the weighted average sale price of the shares of the Issuer's common stock sold, ranging from a low of $0.75 to a high of $0.82 per share. The Reporting Persons undertake, upon request by the staff of the Securities and Exchange Commission, the Issuer, or a securityholder of the Issuer, to provide full information regarding the number of shares sold at each separate price.

F3 · ownership.nature: These shares of the Issuer's common stock are held of record by OrbiMed Private Investments VII, LP ("OPI VII"). OrbiMed Capital GP VII LLC ("GP VII") is the general partner of OPI VII, and OrbiMed Advisors LLC ("OrbiMed Advisors"), a registered investment adviser under the Investment Advisors Act of 1940, as amended, is the managing member of GP VII. By virtue of such relationships, GP VII and OrbiMed Advisors may be deemed to have voting and investment power over the shares of common stock held by OPI VII and, as a result, may be deemed to have beneficial ownership over such shares of common stock. OrbiMed Advisors exercises this investment and voting power through a management committee comprised of Carl L. Gordon, Sven H. Borho, and W. Carter Neild, each of whom disclaims beneficial ownership over the shares of common stock held by OPI VII.

F4 · ownership.nature: Each of OrbiMed Advisors and GP VII disclaims beneficial ownership of the securities reported herein for purposes of Rule 16a-1(a) under the Securities Exchange Act of 1934, as amended (the "Exchange Act"), except to the extent of its pecuniary interest therein, if any. This report shall not be deemed an admission that any such entity is a beneficial owner of such securities for the purpose of Section 16 of the Exchange Act, or for any other purpose.

SEC source: 0000902664-24-006799 · ownership.xml · nonDerivative · entry 3

Lynx1 Capital Management LP · CIK 0001910456 · 10% owner

Nichols Weston · CIK 0001746376 · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: No plan indicated

Ownership: Indirect · See footnote

Disclosed balance after: 8,883,308

F4 · price: The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $0.661 to $0.6838 inclusive. The Reporting Persons undertake to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth herein.

F2 · ownership.nature: The securities to which this filing relates are held directly by Lynx1 Master Fund LP to which Lynx1 Capital Management LP (the "Investment Manager") serves as investment manager. Weston Nichols ("Mr. Nichols") is the sole member of Lynx1 Capital Management GP LLC, the general partner of the Investment Manager. Each of the Investment Manager and Mr. Nichols disclaims beneficial ownership of the securities to which this filing relates for purposes of Section 16 of the Securities and Exchange Act of 1934, as amended, except to the extent of his or its pecuniary interest therein, if any.

SEC source: 0000902664-24-006799 · ownership.xml · nonDerivative · entry 2

Lynx1 Capital Management LP · CIK 0001910456 · 10% owner

Nichols Weston · CIK 0001746376 · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: No plan indicated

Ownership: Indirect · See footnote

Disclosed balance after: 8,854,008

F3 · price: The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $0.65 to $0.77 inclusive. The Reporting Persons undertake to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth herein.

F2 · ownership.nature: The securities to which this filing relates are held directly by Lynx1 Master Fund LP to which Lynx1 Capital Management LP (the "Investment Manager") serves as investment manager. Weston Nichols ("Mr. Nichols") is the sole member of Lynx1 Capital Management GP LLC, the general partner of the Investment Manager. Each of the Investment Manager and Mr. Nichols disclaims beneficial ownership of the securities to which this filing relates for purposes of Section 16 of the Securities and Exchange Act of 1934, as amended, except to the extent of his or its pecuniary interest therein, if any.

SEC source: 0000902664-24-006799 · ownership.xml · nonDerivative · entry 1

Lynx1 Capital Management LP · CIK 0001910456 · 10% owner

Nichols Weston · CIK 0001746376 · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: No plan indicated

Ownership: Indirect · See footnote

Disclosed balance after: 8,686,953

F1 · price: The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $0.49 to $0.65 inclusive. The Reporting Persons undertake to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth herein.

F2 · ownership.nature: The securities to which this filing relates are held directly by Lynx1 Master Fund LP to which Lynx1 Capital Management LP (the "Investment Manager") serves as investment manager. Weston Nichols ("Mr. Nichols") is the sole member of Lynx1 Capital Management GP LLC, the general partner of the Investment Manager. Each of the Investment Manager and Mr. Nichols disclaims beneficial ownership of the securities to which this filing relates for purposes of Section 16 of the Securities and Exchange Act of 1934, as amended, except to the extent of his or its pecuniary interest therein, if any.

SEC source: 0001415889-24-024416 · form4-10022024_081016.xml · derivative · entry 1

Kassberg Thomas Richard · CIK 0001303811 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 174,139

Underlying: Common Stock · 174,139 shares

Expires 2034-09-30

F1 · derivative.exercise_date: The stock option vests as to 1/36 of the total shares monthly beginning on October 10, 2024 until fully vested, subject to the Reporting Person's provision of service to the Issuer on each vesting date.

SEC source: 0001415889-24-024433 · form4-10022024_081040.xml · derivative · entry 1

Cale Edgar B. · CIK 0001799783 · GC & CORPORATE SECRETARY

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 50,000

Underlying: Common Stock · 50,000 shares

Expires 2034-09-30

F1 · derivative.exercise_date: The stock option vests as to 1/48 of the total shares monthly beginning on September 1, 2024 until fully vested, subject to the Reporting Person's provision of service to the Issuer on each vesting date.

SEC source: 0000947871-24-000769 · ownership.xml · nonDerivative · entry 1

ORBIMED ADVISORS LLC · CIK 0001055951 · 10% owner

OrbiMed Capital GP VII LLC · CIK 0001760648 · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: No plan indicated

Ownership: Indirect · See footnotes

Disclosed balance after: 7,794,569

F1 · price: Represents the weighted average sale price of the shares of the Issuer's common stock sold, ranging from a low of $0.70 to a high of $0.73 per share. The Reporting Persons undertake, upon request by the staff of the Securities and Exchange Commission, the Issuer, or a securityholder of the Issuer, to provide full information regarding the number of shares sold at each separate price.

F2 · ownership.nature: These shares of the Issuer's common stock are held of record by OrbiMed Private Investments VII, LP ("OPI VII"). OrbiMed Capital GP VII LLC ("GP VII") is the general partner of OPI VII, and OrbiMed Advisors LLC ("OrbiMed Advisors"), a registered investment adviser under the Investment Advisors Act of 1940, as amended, is the managing member of GP VII. By virtue of such relationships, GP VII and OrbiMed Advisors may be deemed to have voting and investment power over the shares of common stock held by OPI VII and, as a result, may be deemed to have beneficial ownership over such shares of common stock. OrbiMed Advisors exercises this investment and voting power through a management committee comprised of Carl L. Gordon, Sven H. Borho, and W. Carter Neild, each of whom disclaims beneficial ownership over the shares of common stock held by OPI VII.

F3 · ownership.nature: Each of OrbiMed Advisors and GP VII disclaims beneficial ownership of the securities reported herein for purposes of Rule 16a-1(a) under the Securities Exchange Act of 1934, as amended (the "Exchange Act"), except to the extent of its pecuniary interest therein, if any. This report shall not be deemed an admission that any such entity is a beneficial owner of such securities for the purpose of Section 16 of the Exchange Act, or for any other purpose.

SEC source: 0000947871-24-000763 · ownership.xml · nonDerivative · entry 3

ORBIMED ADVISORS LLC · CIK 0001055951 · 10% owner

OrbiMed Capital GP VII LLC · CIK 0001760648 · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: No plan indicated

Ownership: Indirect · See footnotes

Disclosed balance after: 7,833,869

F3 · ownership.nature: These shares of the Issuer's common stock are held of record by OrbiMed Private Investments VII, LP ("OPI VII"). OrbiMed Capital GP VII LLC ("GP VII") is the general partner of OPI VII, and OrbiMed Advisors LLC ("OrbiMed Advisors"), a registered investment adviser under the Investment Advisors Act of 1940, as amended, is the managing member of GP VII. By virtue of such relationships, GP VII and OrbiMed Advisors may be deemed to have voting and investment power over the shares of common stock held by OPI VII and, as a result, may be deemed to have beneficial ownership over such shares of common stock. OrbiMed Advisors exercises this investment and voting power through a management committee comprised of Carl L. Gordon, Sven H. Borho, and W. Carter Neild, each of whom disclaims beneficial ownership over the shares of common stock held by OPI VII.

F4 · ownership.nature: Each of OrbiMed Advisors and GP VII disclaims beneficial ownership of the securities reported herein for purposes of Rule 16a-1(a) under the Securities Exchange Act of 1934, as amended (the "Exchange Act"), except to the extent of its pecuniary interest therein, if any. This report shall not be deemed an admission that any such entity is a beneficial owner of such securities for the purpose of Section 16 of the Exchange Act, or for any other purpose.

SEC source: 0000947871-24-000763 · ownership.xml · nonDerivative · entry 2

ORBIMED ADVISORS LLC · CIK 0001055951 · 10% owner

OrbiMed Capital GP VII LLC · CIK 0001760648 · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: No plan indicated

Ownership: Indirect · See footnotes

Disclosed balance after: 7,859,500

F2 · price: Represents the weighted average sale price of the shares of the Issuer's common stock sold, ranging from a low of $0.73 to a high of $0.75 per share. The Reporting Persons undertake, upon request by the staff of the Securities and Exchange Commission, the Issuer, or a securityholder of the Issuer, to provide full information regarding the number of shares sold at each separate price.

F3 · ownership.nature: These shares of the Issuer's common stock are held of record by OrbiMed Private Investments VII, LP ("OPI VII"). OrbiMed Capital GP VII LLC ("GP VII") is the general partner of OPI VII, and OrbiMed Advisors LLC ("OrbiMed Advisors"), a registered investment adviser under the Investment Advisors Act of 1940, as amended, is the managing member of GP VII. By virtue of such relationships, GP VII and OrbiMed Advisors may be deemed to have voting and investment power over the shares of common stock held by OPI VII and, as a result, may be deemed to have beneficial ownership over such shares of common stock. OrbiMed Advisors exercises this investment and voting power through a management committee comprised of Carl L. Gordon, Sven H. Borho, and W. Carter Neild, each of whom disclaims beneficial ownership over the shares of common stock held by OPI VII.

F4 · ownership.nature: Each of OrbiMed Advisors and GP VII disclaims beneficial ownership of the securities reported herein for purposes of Rule 16a-1(a) under the Securities Exchange Act of 1934, as amended (the "Exchange Act"), except to the extent of its pecuniary interest therein, if any. This report shall not be deemed an admission that any such entity is a beneficial owner of such securities for the purpose of Section 16 of the Exchange Act, or for any other purpose.

SEC source: 0000947871-24-000763 · ownership.xml · nonDerivative · entry 1

ORBIMED ADVISORS LLC · CIK 0001055951 · 10% owner

OrbiMed Capital GP VII LLC · CIK 0001760648 · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: No plan indicated

Ownership: Indirect · See footnotes

Disclosed balance after: 7,970,900

F1 · price: Represents the weighted average sale price of the shares of the Issuer's common stock sold, ranging from a low of $0.73 to a high of $0.78 per share. The Reporting Persons undertake, upon request by the staff of the Securities and Exchange Commission, the Issuer, or a securityholder of the Issuer, to provide full information regarding the number of shares sold at each separate price.

F3 · ownership.nature: These shares of the Issuer's common stock are held of record by OrbiMed Private Investments VII, LP ("OPI VII"). OrbiMed Capital GP VII LLC ("GP VII") is the general partner of OPI VII, and OrbiMed Advisors LLC ("OrbiMed Advisors"), a registered investment adviser under the Investment Advisors Act of 1940, as amended, is the managing member of GP VII. By virtue of such relationships, GP VII and OrbiMed Advisors may be deemed to have voting and investment power over the shares of common stock held by OPI VII and, as a result, may be deemed to have beneficial ownership over such shares of common stock. OrbiMed Advisors exercises this investment and voting power through a management committee comprised of Carl L. Gordon, Sven H. Borho, and W. Carter Neild, each of whom disclaims beneficial ownership over the shares of common stock held by OPI VII.

F4 · ownership.nature: Each of OrbiMed Advisors and GP VII disclaims beneficial ownership of the securities reported herein for purposes of Rule 16a-1(a) under the Securities Exchange Act of 1934, as amended (the "Exchange Act"), except to the extent of its pecuniary interest therein, if any. This report shall not be deemed an admission that any such entity is a beneficial owner of such securities for the purpose of Section 16 of the Exchange Act, or for any other purpose.

SEC source: 0001415889-24-014309 · form4-05232024_080531.xml · derivative · entry 1

Porter Derrell · CIK 0001706400 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 47,693

Underlying: Common Stock · 47,693 shares

Expires 2034-05-21

F1 · derivative.exercise_date: The stock option vests in full on the earlier of: (i) the one year anniversary of the grant date or (ii) the date of the issuer's 2025 Annual Meeting of its stockholders, subject to the reporting person's continuous service to the issuer on such date.

SEC source: 0001415889-24-014313 · form4-05232024_080547.xml · derivative · entry 1

GOWEN MAXINE · CIK 0001280044 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 47,693

Underlying: Common Stock · 47,693 shares

Expires 2034-05-21

F1 · derivative.exercise_date: The stock option vests in full on the earlier of: (i) the one year anniversary of the grant date or (ii) the date of the issuer's 2025 Annual Meeting of its stockholders, subject to the reporting person's continuous service to the issuer on such date.

SEC source: 0001415889-24-014333 · form4-05232024_090550.xml · derivative · entry 1

Countouriotis Athena · CIK 0001571469 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 47,693

Underlying: Common Stock · 47,693 shares

Expires 2034-05-21

F1 · derivative.exercise_date: The stock option vests in full on the earlier of: (i) the one year anniversary of the grant date or (ii) the date of the issuer's 2025 Annual Meeting of its stockholders, subject to the reporting person's continuous service to the issuer on such date.

SEC source: 0001415889-24-014311 · form4-05232024_080531.xml · derivative · entry 1

Islam Saqib · CIK 0001575408 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 47,693

Underlying: Common Stock · 47,693 shares

Expires 2034-05-21

F1 · derivative.exercise_date: The stock option vests in full on the earlier of: (i) the one year anniversary of the grant date or (ii) the date of the issuer's 2025 Annual Meeting of its stockholders, subject to the reporting person's continuous service to the issuer on such date.

SEC source: 0001415889-24-014312 · form4-05232024_080500.xml · derivative · entry 1

Kapadia Sandip · CIK 0001677141 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 47,693

Underlying: Common Stock · 47,693 shares

Expires 2034-05-21

F1 · derivative.exercise_date: The stock option vests in full on the earlier of: (i) the one year anniversary of the grant date or (ii) the date of the issuer's 2025 Annual Meeting of its stockholders, subject to the reporting person's continuous service to the issuer on such date.

SEC source: 0001415889-24-014310 · form4-05232024_080524.xml · derivative · entry 1

Sondhi Dolan · CIK 0001986720 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 39,092

Underlying: Common Stock · 39,092 shares

Expires 2034-05-21

F1 · derivative.exercise_date: The stock option vests in full on the earlier of: (i) the one year anniversary of the grant date or (ii) the date of the issuer's 2025 Annual Meeting of its stockholders, subject to the reporting person's continuous service to the issuer on such date.

SEC source: 0001415889-24-008489 · form4-03192024_080351.xml · derivative · entry 1

Chou William · CIK 0001949693 · Director · PRESIDENT AND CEO

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 575,000

Underlying: Common Stock · 575,000 shares

Expires not disclosed

F1 · derivative.exercise_date: The stock option vests as to 1/48 of the total shares monthly beginning on April 15, 2024 until fully vested, subject to the Reporting Person's provision of service to the Issuer on each vesting date.

F1 · derivative.expiration_date: The stock option vests as to 1/48 of the total shares monthly beginning on April 15, 2024 until fully vested, subject to the Reporting Person's provision of service to the Issuer on each vesting date.

SEC source: 0001415889-24-008491 · form4-03192024_080347.xml · derivative · entry 1

Forman Mark S · CIK 0001922353 · CHIEF MEDICAL OFFICER

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 203,000

Underlying: Common Stock · 203,000 shares

Expires not disclosed

F1 · derivative.exercise_date: The stock option vests as to 1/48 of the total shares monthly beginning on April 15, 2024 until fully vested, subject to the Reporting Person's provision of service to the Issuer on each vesting date.

F1 · derivative.expiration_date: The stock option vests as to 1/48 of the total shares monthly beginning on April 15, 2024 until fully vested, subject to the Reporting Person's provision of service to the Issuer on each vesting date.

SEC source: 0001415889-24-008495 · form4-03192024_080352.xml · derivative · entry 1

Borthwick Kathleen · CIK 0001987062 · CFO

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 227,000

Underlying: Common Stock · 227,000 shares

Expires not disclosed

F1 · derivative.exercise_date: The stock option vests as to 1/48 of the total shares monthly beginning on April 15, 2024 until fully vested, subject to the Reporting Person's provision of service to the Issuer on each vesting date.

F1 · derivative.expiration_date: The stock option vests as to 1/48 of the total shares monthly beginning on April 15, 2024 until fully vested, subject to the Reporting Person's provision of service to the Issuer on each vesting date.

SEC source: 0001415889-24-008487 · form4-03192024_080350.xml · derivative · entry 1

Cale Edgar B. · CIK 0001799783 · GC & CORPORATE SECRETARY

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 203,000

Underlying: Common Stock · 203,000 shares

Expires not disclosed

F1 · derivative.exercise_date: The stock option vests as to 1/48 of the total shares monthly beginning on April 15, 2024 until fully vested, subject to the Reporting Person's provision of service to the Issuer on each vesting date.

F1 · derivative.expiration_date: The stock option vests as to 1/48 of the total shares monthly beginning on April 15, 2024 until fully vested, subject to the Reporting Person's provision of service to the Issuer on each vesting date.

SEC source: 0001415889-24-003637 · form4-02142024_120249.xml · nonDerivative · entry 2

Forman Mark S · CIK 0001922353 · CHIEF MEDICAL OFFICER

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 48,631

F2 · kind: The sale reported on this Form 4 represents an Issuer mandated sale by the Reporting Person to satisfy tax withholding obligations in connection with the vesting and settlement of RSUs; it does not represent a discretionary trade by the Reporting Person. Pursuant to the Issuer's equity incentive plan, an award recipient's tax withholding obligations must be funded by a "sell to cover" transaction.

SEC source: 0001415889-24-003640 · form4-02142024_120246.xml · nonDerivative · entry 2

Borthwick Kathleen · CIK 0001987062 · SVP, INTERIM CFO

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 28,466

F2 · kind: The sale reported on this Form 4 represents an Issuer mandated sale by the Reporting Person to satisfy tax withholding obligations in connection with the vesting and settlement of RSUs; it does not represent a discretionary trade by the Reporting Person. Pursuant to the Issuer's equity incentive plan, an award recipient's tax withholding obligations must be funded by a "sell to cover" transaction.

SEC source: 0001415889-24-003637 · form4-02142024_120249.xml · derivative · entry 6

Forman Mark S · CIK 0001922353 · CHIEF MEDICAL OFFICER

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 10,000

Underlying: Common Stock · 5,000 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · derivative.exercise_price: Restricted stock units ("RSUs") convert into common stock on a one-for-one basis.

F5 · derivative.exercise_date: 1/3 of the RSUs will vest on February 10, 2024 and 2/3 of the RSUs will vest on February 10, 2025, subject to the Reporting Person's continued service to the Issuer on each vesting date.

F5 · derivative.expiration_date: 1/3 of the RSUs will vest on February 10, 2024 and 2/3 of the RSUs will vest on February 10, 2025, subject to the Reporting Person's continued service to the Issuer on each vesting date.

SEC source: 0001415889-24-003637 · form4-02142024_120249.xml · nonDerivative · entry 1

Forman Mark S · CIK 0001922353 · CHIEF MEDICAL OFFICER

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 50,269

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · price: Restricted stock units ("RSUs") convert into common stock on a one-for-one basis.

SEC source: 0001415889-24-003640 · form4-02142024_120246.xml · derivative · entry 3

Borthwick Kathleen · CIK 0001987062 · SVP, INTERIM CFO

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 8,000

Underlying: Common Stock · 4,000 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · derivative.exercise_price: Restricted stock units ("RSUs") convert into common stock on a one-for-one basis.

F3 · derivative.exercise_date: 1/3 of the RSUs will vest on February 10, 2024 and 2/3 of the RSUs will vest on February 10, 2025, subject to the Reporting Person's continued service to the Issuer on each vesting date.

F3 · derivative.expiration_date: 1/3 of the RSUs will vest on February 10, 2024 and 2/3 of the RSUs will vest on February 10, 2025, subject to the Reporting Person's continued service to the Issuer on each vesting date.

SEC source: 0001415889-24-003640 · form4-02142024_120246.xml · nonDerivative · entry 1

Borthwick Kathleen · CIK 0001987062 · SVP, INTERIM CFO

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 29,936

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · price: Restricted stock units ("RSUs") convert into common stock on a one-for-one basis.

SEC source: 0001209191-24-000369 · doc4.xml · nonDerivative · entry 2

Forman Mark S · CIK 0001922353 · Chief Medical Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 45,269

F3 · kind: The sale reported on this Form 4 represents an Issuer mandated sale by the Reporting Person to satisfy tax withholding obligations in connection with the vesting and settlement of RSUs; it does not represent a discretionary trade by the Reporting Person. Pursuant to the Issuer's equity incentive plan, an award recipient's tax withholding obligations must be funded by a "sell to cover" transaction.

SEC source: 0001209191-24-000367 · doc4.xml · nonDerivative · entry 2

Borthwick Kathleen · CIK 0001987062 · SVP, Interim CFO

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 25,936

F3 · kind: The sale reported on this Form 4 represents an Issuer mandated sale by the Reporting Person to satisfy tax withholding obligations in connection with the vesting and settlement of RSUs; it does not represent a discretionary trade by the Reporting Person. Pursuant to the Issuer's equity incentive plan, an award recipient's tax withholding obligations must be funded by a "sell to cover" transaction.

SEC source: 0001209191-24-000365 · doc4.xml · nonDerivative · entry 2

Cale Edgar B. · CIK 0001799783 · GC & Corporate Secretary

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 45,995

F3 · kind: The sale reported on this Form 4 represents an Issuer mandated sale by the Reporting Person to satisfy tax withholding obligations in connection with the vesting and settlement of RSUs; it does not represent a discretionary trade by the Reporting Person. Pursuant to the Issuer's equity incentive plan, an award recipient's tax withholding obligations must be funded by a "sell to cover" transaction.

SEC source: 0001209191-24-000369 · doc4.xml · derivative · entry 3

Forman Mark S · CIK 0001922353 · Chief Medical Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 50,000 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F4 · derivative.exercise_price: Each RSU represents a contingent right to receive one share of Issuer's common stock.

F5 · derivative.exercise_date: 100% of the total restricted stock units vested on December 31, 2023, subject to the Reporting Person's provision of service to the Issuer on each vesting date.

F5 · derivative.expiration_date: 100% of the total restricted stock units vested on December 31, 2023, subject to the Reporting Person's provision of service to the Issuer on each vesting date.

SEC source: 0001209191-24-000369 · doc4.xml · nonDerivative · entry 1

Forman Mark S · CIK 0001922353 · Chief Medical Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 61,082

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · price: Restricted stock units ("RSUs") convert into common stock on a one-for-one basis.

F2 · balance_after: Includes 3,082 shares acquired on May 13, 2022, 4,000 shares acquired on May 15, 2023, and 4,000 shares acquired on November 15, 2023 under the 2020 Employee Stock Purchase Plan.

SEC source: 0001209191-24-000367 · doc4.xml · derivative · entry 3

Borthwick Kathleen · CIK 0001987062 · SVP, Interim CFO

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 30,000 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F4 · derivative.exercise_price: Each RSU represents a contingent right to receive one share of Issuer's common stock.

F5 · derivative.exercise_date: 100% of the total restricted stock units vested on December 31, 2023, subject to the Reporting Person's provision of service to the Issuer on each vesting date.

F5 · derivative.expiration_date: 100% of the total restricted stock units vested on December 31, 2023, subject to the Reporting Person's provision of service to the Issuer on each vesting date.

SEC source: 0001209191-24-000367 · doc4.xml · nonDerivative · entry 1

Borthwick Kathleen · CIK 0001987062 · SVP, Interim CFO

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 36,608

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · price: Restricted stock units ("RSUs") convert into common stock on a one-for-one basis.

F2 · balance_after: Includes 3,082 shares acquired on May 13, 2022 and 3,526 shares acquired on November 15, 2023 under the 2020 Employee Stock Purchase Plan.

SEC source: 0001209191-24-000365 · doc4.xml · derivative · entry 3

Cale Edgar B. · CIK 0001799783 · GC & Corporate Secretary

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 50,000 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F4 · derivative.exercise_price: Each RSU represents a contingent right to receive one share of Issuer's common stock.

F5 · derivative.exercise_date: 100% of the total restricted stock units vested on December 31, 2023, subject to the Reporting Person's provision of service to the Issuer on each vesting date.

F5 · derivative.expiration_date: 100% of the total restricted stock units vested on December 31, 2023, subject to the Reporting Person's provision of service to the Issuer on each vesting date.

SEC source: 0001209191-24-000365 · doc4.xml · nonDerivative · entry 1

Cale Edgar B. · CIK 0001799783 · GC & Corporate Secretary

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 61,808

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · price: Restricted stock units ("RSUs") convert into common stock on a one-for-one basis.

F2 · balance_after: Includes 1,024 shares acquired on May 14, 2021, 531 shares acquired on November 15, 2021, 3,082 shares acquired on May 13, 2022, and 3,967 shares acquired under the 2020 Employee Stock Purchase Plan.

SEC source: 0001209191-23-043725 · doc4.xml · derivative · entry 1

Borthwick Kathleen · CIK 0001987062 · SVP, Interim CFO

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 20,000

Underlying: Common Stock · 20,000 shares

Expires 2033-07-27

F1 · derivative.exercise_date: The stock option vested as to 25% of the total shares on July 28, 2024, and thereafter vests as to 1/48 of the total shares monthly until fully vested, subject to the Reporting Person's provision of service to the Issuer on each vesting date.

SEC source: 0001209191-23-043998 · doc4.xml · derivative · entry 3

King Simona · CIK 0001879312 · Chief Financial Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 31,250 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · derivative.exercise_price: Restricted stock units ("RSUs") convert into common stock on a one-for-one basis.

F3 · derivative.exercise_date: Represents accelerated vesting of RSUs previously granted pursuant to the 2020 Equity Incentive Plan pursuant to a separation agreement between the Reporting Person and the Issuer.

F3 · derivative.expiration_date: Represents accelerated vesting of RSUs previously granted pursuant to the 2020 Equity Incentive Plan pursuant to a separation agreement between the Reporting Person and the Issuer.

SEC source: 0001209191-23-043998 · doc4.xml · nonDerivative · entry 2

King Simona · CIK 0001879312 · Chief Financial Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 23,994

F2 · kind: The sale reported on this Form 4 represents an Issuer mandated sale by the Reporting Person to satisfy tax withholding obligations in connection with the vesting and settlement of RSUs; it does not represent a discretionary trade by the Reporting Person. Pursuant to the Issuer's equity incentive plan, an award recipient's tax withholding obligations must be funded by a "sell to cover" transaction.

SEC source: 0001209191-23-043998 · doc4.xml · nonDerivative · entry 1

King Simona · CIK 0001879312 · Chief Financial Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 35,447

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · price: Restricted stock units ("RSUs") convert into common stock on a one-for-one basis.

SEC source: 0001209191-23-043872 · doc4.xml · derivative · entry 1

Sondhi Dolan · CIK 0001986720 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 48,000

Underlying: Common Stock · 48,000 shares

Expires 2033-07-27

F1 · derivative.exercise_date: The stock option vests as to 1/36 of the total shares on August 28, 2023, and thereafter vests as to 1/36 of the total shares monthly until fully vested, subject to the Reporting Person's provision of service to the Issuer on each vesting date.

SEC source: 0000947871-23-000712 · ownership.xml · nonDerivative · entry 2

ORBIMED ADVISORS LLC · CIK 0001055951 · 10% owner

OrbiMed Capital GP VII LLC · CIK 0001760648 · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: No plan indicated

Ownership: Indirect · See footnotes

Disclosed balance after: 8,034,000

F1 · ownership.nature: These shares of the Issuer's common stock are held of record by OrbiMed Private Investments VII, LP ("OPI VII"). OrbiMed Capital GP VII LLC ("GP VII") is the general partner of OPI VII, and OrbiMed Advisors LLC ("OrbiMed Advisors"), a registered investment adviser under the Investment Advisors Act of 1940, as amended, is the managing member of GP VII. By virtue of such relationships, GP VII and OrbiMed Advisors may be deemed to have voting and investment power over the shares of common stock held by OPI VII and, as a result, may be deemed to have beneficial ownership over such shares of common stock. OrbiMed Advisors exercises this investment and voting power through a management committee comprised of Carl L. Gordon, Sven H. Borho, and W. Carter Neild, each of whom disclaims beneficial ownership over the shares of common stock held by OPI VII.

F2 · ownership.nature: Each of OrbiMed Advisors and GP VII disclaims beneficial ownership of the securities reported herein for purposes of Rule 16a-1(a) under the Securities Exchange Act of 1934, as amended (the "Exchange Act"), except to the extent of its pecuniary interest therein, if any. This report shall not be deemed an admission that any such entity is a beneficial owner of such securities for the purpose of Section 16 of the Exchange Act, or for any other purpose.

SEC source: 0000947871-23-000712 · ownership.xml · nonDerivative · entry 1

ORBIMED ADVISORS LLC · CIK 0001055951 · 10% owner

OrbiMed Capital GP VII LLC · CIK 0001760648 · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: No plan indicated

Ownership: Indirect · See footnotes

Disclosed balance after: 7,458,805

F1 · ownership.nature: These shares of the Issuer's common stock are held of record by OrbiMed Private Investments VII, LP ("OPI VII"). OrbiMed Capital GP VII LLC ("GP VII") is the general partner of OPI VII, and OrbiMed Advisors LLC ("OrbiMed Advisors"), a registered investment adviser under the Investment Advisors Act of 1940, as amended, is the managing member of GP VII. By virtue of such relationships, GP VII and OrbiMed Advisors may be deemed to have voting and investment power over the shares of common stock held by OPI VII and, as a result, may be deemed to have beneficial ownership over such shares of common stock. OrbiMed Advisors exercises this investment and voting power through a management committee comprised of Carl L. Gordon, Sven H. Borho, and W. Carter Neild, each of whom disclaims beneficial ownership over the shares of common stock held by OPI VII.

F2 · ownership.nature: Each of OrbiMed Advisors and GP VII disclaims beneficial ownership of the securities reported herein for purposes of Rule 16a-1(a) under the Securities Exchange Act of 1934, as amended (the "Exchange Act"), except to the extent of its pecuniary interest therein, if any. This report shall not be deemed an admission that any such entity is a beneficial owner of such securities for the purpose of Section 16 of the Exchange Act, or for any other purpose.

SEC source: 0001209191-23-038345 · doc4.xml · nonDerivative · entry 2

Fotopoulos Alexandros · CIK 0001799814 · Chief Technical Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 28,693

F2 · kind: The sale reported on this Form 4 represents an Issuer mandated sale by the Reporting Person to satisfy tax withholding obligations in connection with the vesting and settlement of RSUs; it does not represent a discretionary trade by the Reporting Person. Pursuant to the Issuer's equity incentive plan, an award recipient's tax withholding obligations must be funded by a "sell to cover" transaction.